Effect of anti-VEGF treatment on retinopathy of prematurity in Zone II Stage 3.

AIM: To evaluate the effect of intravitreal ranibizumab injection for retinopathy of prematurity (ROP) in Zone II Stage 3+. METHODS: Data was collected for ROP patients with Zone II Stage 3+ who received intravitreal ranibizumab injections between October 2014 and Janu-ary 2017 at the Department of Ophthalmology in our hospital. No prior laser or other intravitreal treatment was done. Prior to the intervention and at each follow-up visit, fundus examination was performed. Gestational age at birth, sex, birth weight, ROP zone, ROP stage, post menstrual age (PMA) at treatment, and follow-up pe-riod were recorded. The final clinical status of the retina was evaluated for each patient. The primary outcome mea-sures included ROP recurrences requiring re-treatment, complete or incomplete peripheral vascularization. RESULTS: Eighty-six eyes of 46 premature infants with Zone II Stage 3+ ROP were enrolled in the study. The mean gestational age at birth was 28.18±1.67 (range: 25 to 33)wk and the mean birth weight was 1070.57±226.85 (range: 720.00 to 1650.00) g. The mean PMA at treatment was 38.32±2.99 (range: 32.29 to 46.00)wk. Seventy-one eyes (82.56%) were treated success-fully with intravitreal ranibizumab as monotherapy. Fifteen eyes (17.44%) developed recurrent disease. The mean interval between the treatment and retreatment was 5.96±3.22 (range: 1.86 to 11.71)wk. All eyes vascularized into zone III at the end of the study and among them 62 eyes (72.09%) achieved complete vascu-larization. CONCLUSION: Intravitreal ranibizumab injection is an effective treatment in Zone II Stage 3+ ROP patients. More patients with longer follow-up duration are necessary to confirm the safety and efficacy of this treatment.

[The relationship between high-sensitivity C-reactive protein (hsCRP) levels and atrial fibrillation early recurrence after paroxysmal atrial fibrillation radiofrequency catheter ablation].

OBJECTIVE: To prospectively clarify the predictive value of high-sensitivity C-reactive protein (hsCRP) on the risk for recurrent atrial arrhythmia in paroxysmal atrial fibrillation (PAF) population who accepted radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF). METHODS: There were 57 consecutive patients (53.32±9.98 years; 42 males) with drug-refractory PAF who underwent RFCA were included. Plasma levels of hsCRP and high-sensitivity cardiac troponin T (hs-cTnT) were measured on admission and first five days after RFCA. Twenty-five patients (43.86%) had early recurrence of atrial fibrillation (ERAF). RESULTS: Compared to patients without ERAF (no-AF-recurrence group), baseline hsCRP levels had no significant difference in patients with ERAF (AF recurrence group). There were no significant differences in the peak hsCRP and hs-cTnT levels between no-AF-recurrence group and AF recurrence group. However, change of hsCRP level was significantly correlated with change in hs-cTnT level in patients undergoing RFCA (r=0.268, P=0.044). CONCLUSIONS: Among those AF patients undergoing ablation, change of hsCRP level could be for the myocardial injury related to RFCA procedure, which may not be a risk factor to predict ERAF. The variety of hsCRP level may be related to the degree of myocardial injury induced by RFCA.

Cancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trials.

BACKGROUND: Although statins are well tolerated by most aged people, their potential carcinogenicity is considered as one of the biggest factors limiting the use of statins. The aim of the present study was to determine the risk of cancer in people aged over 60 years receiving statin therapy. METHODS: A comprehensive search for articles published up to December 2015 was performed, reviews of each randomized controlled trials (RCTs) that compared the effects of statin mono-therapy with placebo on the risk of cancer in people aged > 60 years were conducted and data abstracted. All the included studies were evaluated for publication bias and heterogeneity. Pooled odds ratios (OR) estimates and 95% confidence intervals (CIs) were calculated using the random effects model. RESULTS: A total of 12 RCTs, involving 62,927 patients (31,517 in statin therapy group and 31,410 in control group), with a follow-up duration of 1.9-5.4 years, contributed to the analysis. The statin therapy did not affect the overall incidence of cancer (OR = 1.03, 95% CI: 0.94-1.14, P = 0.52); subgroup analyses showed that neither the variety nor the chemical properties of the statins accounted for the incidence of cancer in older people. CONCLUSIONS: Our meta-analysis findings do not support a potential cancer risk of statin treatment in people over 60 years old. Further targeted researches with a longer follow-up duration are warranted to confirm this issue.

Impact of body mass index on the development of pocket hematoma: A retrospective study in Chinese people.

BACKGROUND: Pocket hematoma is one of the major complications associated with cardiovascular implantable electronic devices (CIEDs) implantation. The aim of this study is to evaluate the impact of body mass index (BMI) on the occurrence of pocket hematoma after CIEDs implantation. METHODS: The study is a retrospective review of 972 patients receiving CIEDs implantation between 2008 and 2012 in a tertiary hospital. RESULTS: Twenty two patients (2.2%) developed severe pocket hematoma requiring re-intervention. The hematoma rate (4.6%, n = 15) of patients with a BMI of < 23 kg/m(2) was significantly higher compared with that of patients with a BMI of ≥ 23 kg/m(2) (1.1%, n = 7, P < 0.001). In multivariate regression analysis, a BMI < 23.0 kg/m(2) may be associated with the development of severe pocket hematoma. An increase of 1.0 kg/m(2) in BMI was associated with lower incidence of hematoma formation (OR: 0.84; 95% CI: 0.74-0.95; P = 0.006). CONCLUSION: BMI < 23 kg/m(2) was associated with a higher incidence of pocket hematoma, requiring re-intervention. The data support that great care must be taken when patients were with a lower BMI received CIEDs implantation.

Resistin might not be a risk factor for carotid artery atherosclerosis in elderly Chinese males.

OBJECTIVE: To investigate the correlation between the serum resistin level and carotid artery atherosclerosis in elderly Chinese males. METHODS: The study enrolled 235 elderly Chinese males [median age 76 (range 60-97) years] scheduled for ultrasound examination of carotid artery plaque and determination of carotid artery intima-media thickness (CIMT). They were divided into carotid atherosclerotic plaque (CAP) and carotid atherosclerotic plaque-free (CAP-free) groups according to the ultrasound results. Their clinical profiles were collected, and the serum resistin and other blood biochemistry levels were determined. RESULTS: The CAP group was older and had a thicker mean CIMT than the CAP-free group. However, there was no difference in the serum resistin level between the groups. CIMT was positively correlated with age (r = 0.299, P < 0.001). The serum resistin level was not correlated with CIMT, even after controlling for age. Multiple linear regression analysis revealed that age (ß = 0.001, P < 0.001) and body mass index (ß = 0.002, P = 0.015) were significantly and positively correlated with the mean CIMT. Only age [odds ratio (OR): 1.159; 95% confidence interval (CI): 1.078-1.183, P < 0.001] was associated with the presence of carotid artery atherosclerotic plaque. The serum resistin level was not correlated with the mean CIMT or associated with the presence of carotid artery atherosclerotic plaque. CONCLUSION: The results suggest that resistin might not be a risk factor for atherosclerosis in elderly Chinese males.

[Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure].

OBJECTIVE: To investigate the effect of metoprolol on the expression of G protein-coupled receptor kinases 2 (GRK2) in lymphocyte of advanced elderly patients with chronic heart failure. METHODS: 32 elderly patients with chronic heart failure were divided into control group and metoprolol group, 16 each. Conventional therapy was used in the control group, conventional therapy plua metoprolol was used in metoprolol group. The treatment courses were 8 weeks in both groups. RESULTS: Left ventricular end-diastolic diameter and left ventricular ejection fraction were not different between the two groups. Lymphocyte GRK2 mRNA level in metoprolol group was lower than that in control group. CONCLUSION: Metoprolol can inhibit the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure.